CA3060143A1 - Novel psma-binding agents and uses thereof - Google Patents

Novel psma-binding agents and uses thereof Download PDF

Info

Publication number
CA3060143A1
CA3060143A1 CA3060143A CA3060143A CA3060143A1 CA 3060143 A1 CA3060143 A1 CA 3060143A1 CA 3060143 A CA3060143 A CA 3060143A CA 3060143 A CA3060143 A CA 3060143A CA 3060143 A1 CA3060143 A1 CA 3060143A1
Authority
CA
Canada
Prior art keywords
psma
acid
alb
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3060143A
Other languages
English (en)
French (fr)
Inventor
Martina Benesova
Cristina Muller
Christoph UMBRICHT
Roger Schibli
Konstantin Zhernosekov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paul Scherrer Institute
ITM Isotope Technologies Munich SE
Original Assignee
Paul Scherrer Institute
ITM Isotope Technologies Munich SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/000717 external-priority patent/WO2018233798A1/en
Application filed by Paul Scherrer Institute, ITM Isotope Technologies Munich SE filed Critical Paul Scherrer Institute
Publication of CA3060143A1 publication Critical patent/CA3060143A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5229—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image
    • A61B6/5235—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image combining images from the same or different ionising radiation imaging techniques, e.g. PET and CT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3060143A 2017-05-24 2018-05-24 Novel psma-binding agents and uses thereof Pending CA3060143A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17000891 2017-05-24
EP17000891.6 2017-05-24
EPPCT/EP2017/000717 2017-06-20
PCT/EP2017/000717 WO2018233798A1 (en) 2017-06-20 2017-06-20 NOVEL PSMA BINDING AGENTS AND USE THEREOF
PCT/EP2018/063734 WO2018215627A1 (en) 2017-05-24 2018-05-24 Novel psma-binding agents and uses thereof

Publications (1)

Publication Number Publication Date
CA3060143A1 true CA3060143A1 (en) 2018-11-29

Family

ID=62200468

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3060143A Pending CA3060143A1 (en) 2017-05-24 2018-05-24 Novel psma-binding agents and uses thereof

Country Status (9)

Country Link
US (1) US11629201B2 (enExample)
EP (1) EP3630204B1 (enExample)
JP (1) JP7340459B2 (enExample)
KR (1) KR102843240B1 (enExample)
CN (1) CN110740757B (enExample)
AU (1) AU2018274184B2 (enExample)
CA (1) CA3060143A1 (enExample)
WO (1) WO2018215627A1 (enExample)
ZA (1) ZA201906832B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018352731B2 (en) * 2017-10-22 2023-10-05 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
EP3887795A1 (en) * 2018-11-30 2021-10-06 Perkinelmer Health Sciences Inc. Biological sample preparation using electric fields
CA3127188A1 (en) * 2019-01-17 2020-07-23 Case Western Reserve University Peptide pet/spect probes specific to oncoproteins in tumor extracellularmatrix
EP3976025A4 (en) * 2019-05-24 2023-05-17 Clarity Pharmaceuticals Limited PSMA IMAGING AGENT FORMULATIONS
WO2020252598A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
TWI803688B (zh) * 2019-08-26 2023-06-01 行政院原子能委員會核能研究所 一種psma靶向放射診療藥物備製方法
KR102269315B1 (ko) * 2019-10-24 2021-06-24 서울대학교산학협력단 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
EP4244216A1 (en) * 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
US20240174622A1 (en) * 2021-03-04 2024-05-30 Nihon Medi-Physics Co., Ltd. Compound and radioactive labeling compound
CN116940557A (zh) * 2021-03-04 2023-10-24 日本医事物理股份有限公司 化合物及放射性标记化合物
EP4341296A4 (en) * 2021-05-21 2025-07-30 Northstar Medical Tech Llc RADIOPHARMACEUTICAL PRODUCT TARGETING THE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR
JP2024532521A (ja) 2021-09-03 2024-09-05 晶核生物医藥科技（南京）有限公司 ペプチド－尿素誘導体、それを含む医薬組成物、及びそれらの使用
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
US20250222143A1 (en) * 2021-10-20 2025-07-10 The Research Foundation For The State University Of New York Targeted radiotheranostics based on polyazamacrocyclic, mixed-donor scaffolds linked to a targeting vector
WO2023083209A1 (zh) * 2021-11-10 2023-05-19 苏州瑞核医药科技有限公司 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用
EP4436979A4 (en) * 2021-11-26 2026-06-10 Full Life Tech Uk Limited Cleftable radioligands for targeting cell surface receptors and their uses
CA3244865A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
US20260083865A1 (en) * 2022-09-07 2026-03-26 3B Pharmaceuticals Gmbh Prostate specific membrane antigen (psma) ligands and use thereof
TW202410923A (zh) * 2022-09-09 2024-03-16 大陸商同宜醫藥（蘇州）有限公司 放射性核種偶聯藥物及其藥物組成物和應用
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
IL319722A (en) 2022-09-23 2025-05-01 Nuclidium Ag High purity radionuclides and their diagnostic and medical uses
EP4667019A1 (en) * 2023-02-16 2025-12-24 Norroy Bioscience Co., Ltd. Psma-targeted radiopharmaceutical, and synthesis and use thereof
EP4719498A1 (en) * 2023-05-31 2026-04-08 Full-Life Technologies UK Limited Radioligands for targeting cell surface receptors and uses thereof
EP4719486A1 (en) * 2023-05-31 2026-04-08 Full-Life Technologies UK Limited Conjugates and uses thereof
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof
WO2025088147A1 (en) * 2023-10-27 2025-05-01 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis
WO2025218879A1 (en) 2024-04-15 2025-10-23 Itm Technologies Munich Se Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same
EP4763231A1 (en) 2024-12-20 2026-06-24 ITM Isotope Technologies Munich SE Para-aminohippuric acid as a stabilizer in radiopharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US9687572B2 (en) * 2010-12-06 2017-06-27 Molecular Insight Pharmaceuticals, Inc. PSMA-targeted dendrimers
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
DK2766364T3 (da) 2011-08-17 2024-09-30 Merck & Cie Folatkonjugater af albumin-bindende enheder
SMT202300035T1 (it) 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX392700B (es) 2016-08-10 2025-03-11 Cancer Targeted Tech Llc Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer

Also Published As

Publication number Publication date
AU2018274184B2 (en) 2024-06-13
KR20200009091A (ko) 2020-01-29
JP7340459B2 (ja) 2023-09-07
US11629201B2 (en) 2023-04-18
ZA201906832B (en) 2024-02-28
CN110740757B (zh) 2023-04-04
RU2019141963A (ru) 2021-06-24
WO2018215627A1 (en) 2018-11-29
EP3630204A1 (en) 2020-04-08
KR102843240B1 (ko) 2025-08-05
US20210009715A1 (en) 2021-01-14
EP3630204B1 (en) 2026-07-01
RU2019141963A3 (enExample) 2021-09-22
AU2018274184A1 (en) 2019-11-07
JP2020520902A (ja) 2020-07-16
CN110740757A (zh) 2020-01-31

Similar Documents

Publication Publication Date Title
AU2018274184B2 (en) Novel PSMA-binding agents and uses thereof
AU2019386997B2 (en) Novel tumor antigen binding agents and uses thereof
US20250057993A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
AU2018308699B2 (en) Dual mode radiotracer and -therapeutics
CA2924360C (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA3004696A1 (en) Peptide thiourea derivative, radioisotope labeled compound containing same, and pharmaceutical composition containing same as active ingredient for treating or diagnosing prostatecancer
CN107438615B (zh) 用于制备放射性核素络合物的方法和试剂盒
CA3171753A1 (en) Stable formulations for radionuclide complexes
CA2969551A1 (en) Bifunctional do2pa derivatives, chelates with metallic cations and use thereof
CA3210294A1 (en) Compound and radioactive labeling compound
WO2024193724A1 (zh) 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
KR20240099330A (ko) 위 억제 펩티드 수용체 리간드
WO2018233798A1 (en) NOVEL PSMA BINDING AGENTS AND USE THEREOF
CN117120099A (zh) 双模式放射性示踪剂和疗法
KR101918205B1 (ko) 바이페닐 함유 rgd 유도체, 그 제조방법 및 그것을 포함하는 방사성의약품
RU2787105C2 (ru) Новые пса-связывающие агенты и их применение
RU2831681C2 (ru) Новые связывающие опухолевый антиген агенты и их применение
HK40054611A (en) Novel tumor antigen binding agents and uses thereof
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
IL324113A (en) Gastric inhibitory peptide receptor ligands with bio-distribution modifier

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220916

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240715

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241101

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250325

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250325

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250328

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250328

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250519

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250519

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250730

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251119

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260107

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260107

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260507

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260511

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260511

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20260520

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260520